NCT07157371

Brief Summary

Design: RCT Randomized Clinical Trial Non Probability Convenient Sampling Technique Duration of treatment: 25 weeks 2 groups; (group A=30) SSAET +Normal routine medication+ Normal Dietary Plan , Other group (Group B=30) with normal routine medication + Normal Dietary Plan. Patients will be enrolled in experimental group according to speeds test. HYPOTHESIS: Alternate hypothesis: There is difference on the effects of Supervised Structured Aerobic Exercise Training Program on serum BDNF, androgens level, menstrual irregularity and quality of life in females with insulin resistant polycystic ovarian syndrome. Null Hypothesis: There is no difference on the effects of Supervised Structured Aerobic Exercise Training Program on serum BDNF, androgens level, menstrual irregularity and quality of life in females with insulin resistant polycystic ovarian syndrome. OBJECTIVES: To determine the effects of Supervised Structured Aerobic Exercise Training Program on quality of life in women with PCOS. 2\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on BDNF levels in women with PCOS. 3\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on mental health (stress, depression, anxiety) in women with PCOS. 4\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on BMI in women with PCOS. 5\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on menstrual irregularity in women with PCOS. 6\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on Aerobic fitness in women with PCOS. 7\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on androgens level in PCOS. 8\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on Lipid accumulation product in PCOS. 9\. To determine the effect of Supervised Structured Aerobic Exercise Training Program on Glycemic control in PCOS.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 3, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 5, 2025

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

September 5, 2025

Status Verified

August 1, 2025

Enrollment Period

6 months

First QC Date

August 3, 2025

Last Update Submit

August 28, 2025

Conditions

Keywords

Insulin resistantSupervisedaerobic exerciseSSAETPCOSmetabolic syndrome

Outcome Measures

Primary Outcomes (6)

  • Depression Anxiety Stress Scale (DASS)

    Mental Health (Stress, depression \& Anxiety) by DASS 21 Scoring Process: 1. Sum the scores for each subscale: Add the scores for the 7 items within each subscale (Depression, Anxiety, and Stress). 2. Multiply by 2: Multiply the sum of each subscale by 2 to get the final score for each area (Depression, Anxiety, and Stress). 3. Interpret the scores: The resulting scores are then interpreted using the provided severity levels for each subscale. Severity Levels: The DASS-21 provides severity levels for each subscale: Depression: Normal (0-9), Mild (10-13), Moderate (14-20), Severe (21-27), Extremely Severe (28+). Anxiety: Normal (0-7), Mild (8-9), Moderate (10-14), Severe (15-19), Extremely Severe (20+). Stress: Normal (0-14), Mild (15-18), Moderate (19-25), Severe (26-33), Extremely Severe (34+). \> Higher the scores means more severity and less healthy.

    12 weeks and 25 weeks

  • Polycystic ovarian syndrome Quality of Life Questionnaire (PCOSQOL)

    This is a tool to measure quality of life in females with Polycystic Ovarian syndrome. There are total 35 Questions in it. Scoring: Summate each item to give a total score. A low score represents that a lower quality of life, a higher score represents a lesser to no impact on quality of life.

    12 weeks and 25 weeks

  • MIQ (Menstrual Irregularity Questionnaire)

    Measures menstrual irregularity The MIQ is a 6-point questionnaire, and the total score reflects the overall impact of heavy menstrual bleeding on the woman's life. Higher scores indicate a greater negative impact of heavy menstrual bleeding on the woman's quality of life. The MIQ helps healthcare professionals understand the severity of the problem and tailor treatment accordingly.

    12 weeks and 25 weeks

  • 3 min bench step test II. Indirect estimation of VO2 max by formula VO2 max (walking) = (0.2 x speed of treadmill) + (0.9 x speed x treadmill grade) + 3.5

    To measure Aerobic fitness. YMCA 3-minute Bench Step Test: You step up and down on a 30 cm (12-inch) step for three minutes at a consistent pace, and your heart rate is measured afterward to estimate fitness for 1 minute through carotid artery. The more fit you are, the lower your recovery heart rate will be, meaning a lower number is a better score. Compare to Charts: Use your age and gender to find the appropriate fitness rating chart, such as the YMCA charts. Determine Your Level: The chart will show whether your 1-minute heart rate falls into categories like excellent, good, above average, average, or below average fitness. YMCA FEMALES Scoring: Excellent \<109 Above Average 110 - 117 Average 118 - 134 Below Average 135-137 Poor \>137

    12 weeks and 25 weeks

  • ELISA

    BDNF levels

    12 and 25 weeks

  • Androgens level

    Serum SHBG will be measured by coated-tube immunoradiometric assay using commercial kits. Testosterone will be measured by RIA using commercial enzymatic kits. Free androgen index (FAI) will be calculated as testosterone/SHBG Ă— 100. Clinical hyperandrogenism (a score of 6 or higher on the modified Ferriman-Gallwey scale)

    12 weeks and 25 weeks

Secondary Outcomes (3)

  • HOMA-IR for Glycemic control

    12 weeks and 25 weeks

  • Lipid Accumulation Product

    12 weeks and 25 weeks

  • BMI

    12 weeks and 25 weeks

Study Arms (2)

Interventional group- PCOS

EXPERIMENTAL

25 weeks of supervised structured aerobic exercise treatment program will be applied on the females with PCOS in the gym setting.

Other: Supervised structured aerobic exercise training

Second group- PCOS

ACTIVE COMPARATOR

walk will be asked for these patients and their feedback will be taken through cell phone

Other: Walk

Interventions

Supervised structured aerobic exercise plan will be conducted in gym by the physiotherapist

Also known as: Aerobic exercises
Interventional group- PCOS
WalkOTHER

Females with PCOS will be instructed to do a walk at home with medications

Second group- PCOS

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailsfemales only who are diagnosed by the gynecologist with polycystic ovarian syndrome according to Rotterdum criteria of diagnosing PCOS.
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18 To 35 years Females.
  • Insulin resistant PCOS type.
  • Already Diagnosed patients form gynecological department according to the Rotterdam criteria.
  • Both Married and unmarried females.
  • Nulliparous females.

You may not qualify if:

  • Post pill PCOS, Inflammatory PCOS \& Adrenal PCOS
  • Any psychological disease or disorder
  • Any systemic disease other than PCOS (cushing syndrome, thyroid dysfunction, etc)
  • Orthopedic conditions (including fracture, dislocation, etc)
  • Any surgery in past 6 months.
  • Involved in any other exercise regimen at the same time.
  • Having any specialized diet plan.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sculpture Gym

Lahore, 53710, Pakistan

Location

Related Publications (1)

  • Shakil-Ur-Rehman S, Karimi H, Gillani SA. Effects of supervised structured aerobic exercise training program on fasting blood glucose level, plasma insulin level, glycemic control, and insulin resistance in type 2 diabetes mellitus. Pak J Med Sci. 2017 May-Jun;33(3):576-580. doi: 10.12669/pjms.333.12023.

Related Links

MeSH Terms

Conditions

Polycystic Ovary SyndromeMetabolic Syndrome

Interventions

ExerciseWalking

Condition Hierarchy (Ancestors)

Ovarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System DiseasesInsulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaLocomotion

Study Officials

  • Muzna Munir, ppdpt

    Riphah International University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

August 3, 2025

First Posted

September 5, 2025

Study Start

April 1, 2025

Primary Completion

September 30, 2025

Study Completion

October 1, 2025

Last Updated

September 5, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Available IPD Datasets

Study Protocol (PMID: 28811774)Access

Locations